期刊文献+

室间隔缺损血清候选标志物锌指蛋白41的验证研究

Verification of ZNF41 as a serum candidate biomarker for ventricular septal defect
原文传递
导出
摘要 目的验证锌指蛋白41(zinc finger protein 41,ZNF41)是否为室间隔缺损(ventricular septal defect,VSD)患者的血清候选标志物。方法收集室间隔缺损患者的血清和与之性别、年龄、民族等频数相匹配的房间隔缺损(atrial septal defect,ASD)患者、法洛四联症(tetralogy of Fallot,TOF)患者和健康对照者的血清各20例,应用蛋白免疫印迹(Western blot)和酶联免疫吸附测定(enzyme-linked immunosorbent assay,ELISA)检测各组血清样本中锌指蛋白41的表达水平。结果 Western blot检测结果显示,锌指蛋白41在4组血清中均有表达,但VSD组中的相对表达水平均高于其他3组(均有P<0.05);ELISA检测结果可知VSD组的血清锌指蛋白41浓度为(136.72±56.44)pg/ml,ASD组为(94.54±41.98)pg/ml,TOF组为(100.69±37.08)pg/ml,健康对照组为(82.08±42.46)pg/ml,4组间差异有统计学意义(P=0.008),进一步两两比较,VSD组与其他3组之间差异均有统计学意义(均有P<0.05),而其他3组两两间差异均无统计学意义(均有P>0.05)。结论锌指蛋白41在VSD患者血清中表达水平较高,可能是VSD的血清候选标志物。 Objective To validate zinc finger protein 41( ZNF41) as a serum candidate biomarker in patients with ventricular septal defect( VSD). Methods The serum samples were obtained from patients with VSD,atrial septal defect( ASD),tetralogy of Fallot( TOF),and healthy controls. Each group had 20 study subjects. The four groups were frequency matched in age,gender,and nationality,respectively. The expression levels of ZNF41 in serum samples were detected by Western blot and enzyme-linked immunosorbent assay( ELISA). Results Western blot results showed that ZNF41 was detectable in all samples of study subjects. However,the relative expression level of ZNF41 in VSD group was higher than that in the other three groups( all P < 0. 05). The results of ELISA showed that the serum concentrations of ZNF41 in VSD,ASD,TOF and healthy group were( 136. 72 ± 56. 44) pg /ml,( 94. 54 ± 41. 98) pg /ml,( 100. 69 ±37. 08) pg /ml,and( 82. 08 ± 42. 46) pg /ml,respectively. There were statistically significant differences among the four groups( F = 4. 33,P = 0. 008). Given the further comparisons between each two groups,there was statistically significant difference between VSD group and the other three groups respectively( all P < 0. 05). Besides,there was no statistically significant difference between each two groups in the other three groups( all P > 0. 05). Conclusions The concentration of ZNF41 is higher in serum of patients with VSD,which suggests that ZNF41 may be used as a serum candidate biomarker for VSD.
出处 《中华疾病控制杂志》 CAS 北大核心 2014年第9期801-804,共4页 Chinese Journal of Disease Control & Prevention
基金 国家自然科学基金(81360440)
关键词 室间隔缺损 锌指 生物学标记 Heart septal defects,ventricular Zinc fingers Biological markers
  • 相关文献

参考文献13

  • 1仇小强,张永波,曾小云,何敏,周怡,罗蓉,李洪涛,余红平.室间隔缺损生物标志物血清蛋白质组学分析[J].中国公共卫生,2013,29(6):828-831. 被引量:5
  • 2潘健源,袁昌翮,高潮,陈振飞,冯俊.肥东县婴幼儿先天性心脏病的流行病学调查[J].中华疾病控制杂志,2013,17(5):446-446. 被引量:6
  • 3张江,孔佩艳.蛋白质芯片在恶性肿瘤研究中的应用[J].中华疾病控制杂志,2010,14(3):263-265. 被引量:2
  • 4Emily Boja,Robert Rivers,Christopher Kinsinger,Mehdi Mesri,Tara Hiltke,Amir Rahbar,Henry Rodriguez.Restructuring proteomics through verification[J].Biomarkers Med.2010(6)
  • 5Brigitte Laforest,Mona Nemer.GATA5 interacts with GATA4 and GATA6 in outflow tract development[J].Developmental Biology.2010(2)
  • 6Dao-Fu Dai,Peterus Thajeb,Cheng-Fen Tu,Fu-Tien Chiang,Chien-Hsiun Chen,Ruey-Bing Yang,Jin-Jer Chen.Plasma Concentration of SCUBE1, a Novel Platelet Protein, Is Elevated in Patients With Acute Coronary Syndrome and Ischemic Stroke[J].Journal of the American College of Cardiology.2008(22)
  • 7Vicki L. Zeigler.Congenital Heart Disease and Genetics[J].Critical Care Nursing Clinics of North America.2008(2)
  • 8GAndelfinger.Genetic factors in congenital heart malformation[J].Clinical Genetics.2008(6)
  • 9Kathryn J. Brayer,David J. Segal.Keep Your Fingers Off My DNA: Protein–Protein Interactions Mediated by C2H2 Zinc Finger Domains[J].Cell Biochemistry and Biophysics.2008(3)
  • 10Yongqing Li,Dan Yang,Yan Bai,Xiaoyang Mo,Wen Huang,Wuzhou Yuan,Zhaochu Yin,Yun Deng,Oleg Murashko,Yuequn Wang,Xiongwei Fan,Chuanbing Zhu,Karen Ocorr,Rolf Bodmer,Xiushan Wu.ZNF418, a novel human KRAB/C2H2 zinc finger protein, suppresses MAPK signaling pathway[J].Molecular and Cellular Biochemistry (-).2008(1-2)

二级参考文献27

  • 1Kijanka G, Murphy D. Protein arrays as tools for serum autoanti-body marker discovery in cancer[J].J Proteomics, 2009,72 (6) :936-944.
  • 2Becker KF, Metzger V,Hipp S, et al. Clinical Proteomics: New Trends for Protein Microarrays [J]. Curr Med Chem, 2006, 13(15) : 1831-1837.
  • 3Tao SC, Chen CS, Zhu H. Applications of Protein Microarray Technology [J ]. Comb Chem High Throughput Screen, 2007,10 (8) :706-718.
  • 4Bertone P, Snyder M. Advances in functional protein microarray technology[J]. FEBS J, 2005,272(21) :5400-5411.
  • 5Netterwald J. Protein Microarrays in Cancer Research [J]. G&P, 2006,6(6) :8-G10.
  • 6Hudson ME, Pozdnyakova I, Haines K, et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein mieroarrays [J]. Proc Nat Acad Sci, 2007,104(44) : 17494 - 17499.
  • 7Gunawardana CG, Mernari N, Diamandis EP. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays [J ]. Clin Biochem, 2009,42 (4-5) : 426-429.
  • 8Zhong L, Hidalgo GE, Stromberg A J, et al. Using Protein Microarray as a Diagnostic Assay for Non-Small Cell Lung Cancer [J]. Am J Respir Cri Care IVied, 2005,172(10) :1308-1314.
  • 9Gnjatic S, Wheeler C, Ebner M, et al. Seromic analysis of anti-body responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays [J ]. J Immunol Methods, 2009,341(1-2) :50-58.
  • 10Drenes-Pinero E, Barderas R, Rico D, et al. Serological autoantibody profiling using protein arrays distinguish bladder cancer patients from contrals[J]. J Urol, 2009,181(4):417.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部